SCHEMBL4741302

SCHEMBL4741302

COC(=O)c1cccc(-c2nc(O)cc(=O)[nH]2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 1/20 0.49
PDE2A O00408 1/20 0.48
ERN1 O75460 2/20 0.46
ERCC1 P07992 1/20 0.46
FEN1 P39748 1/20 0.46
ERCC4 Q92889 1/20 0.46
KDM5B Q9UGL1 1/20 0.45
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA5 P31644 1/20 0.44
GABRA3 P34903 1/20 0.44
MAPK14 Q16539 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
TNKS O95271 1/20 0.43
PLAU P00749 1/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4739118 0.83 HPGD (0.58) ERCC1FEN1ERCC4CA12CA1
SCHEMBL27949967 0.82 CDK8 (0.55) CDK8ERN1GABRG2GABRB3GABRA5
SCHEMBL3335676 0.76 KDM4E (0.74) ALDH1A1HPGDNPC1RAB9AKDM4E
SCHEMBL259248 0.76 TNKS (0.58) ERCC1FEN1ERCC4TNKSALDH1A1
SCHEMBL31420315 0.75 CDK8 (0.47) CDK8ERN1KDM5BGABRG2GABRB3
SCHEMBL67941 0.74 CA12 (0.68) CDK8ERN1GABRG2GABRB3GABRA5
SCHEMBL4939590 0.74 ALOX15 (0.51) CDK8KDM5BTNKSALDH1A1HPGD
SCHEMBL7461576 0.74 CDK8 (0.55) CDK8ERN1GABRG2GABRB3GABRA5
SCHEMBL9493590 0.74 ALOX5 (0.47) HPGDL3MBTL1KDM4EPKM
SCHEMBL17279808 0.74 CDK8 (0.55) CDK8ERN1KDM5BGABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 CDK8 2485/4885PDE2A 2134/4885ERN1 2420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.